Group 1 - The core viewpoint of the news highlights the significant surge in the brain-computer interface (BCI) sector, driven by advancements and investments, particularly from Elon Musk's Neuralink, which plans to start large-scale production of BCI devices by 2026 [1] - The China Securities Regulatory Commission has included BCI in future industries, with a two-step development goal set for the next five years, indicating strong governmental support for the sector [1] - The medical device ETF (159883) has shown a notable increase of 5.54%, with a net subscription exceeding 181 million units, reflecting investor confidence in the BCI and medical technology sectors [1] Group 2 - The application of BCI technology in medical fields, particularly for mental health, rehabilitation, and health management, is expected to accelerate due to supportive policies [2] - The medical device ETF (159883) tracks the medical device sector and has a strong technological focus, with over 80% of its components coming from the Sci-Tech Innovation Board and the Growth Enterprise Market [2] - The Hong Kong medical ETF (159366) has also performed well, rising 5.34%, with significant gains in individual stocks related to brain science and medical technology [3]

Group 1 - The brain-computer interface (BCI) sector is experiencing significant growth, with companies like Neuralink and Merge Labs leading the charge in invasive and non-invasive technologies respectively [1][2] - Neuralink plans to begin large-scale production of its BCI devices in 2026, introducing a streamlined and automated surgical process that avoids traditional invasive methods [1] - Zhejiang Qiangnao Technology Co., Ltd. is emerging as a domestic unicorn in the BCI field, focusing on non-invasive technology and aiming for an IPO in mainland China or Hong Kong by 2026 [2] Group 2 - Qiangnao Technology has formed a strategic partnership with Lingyi iTech, enhancing both companies' market competitiveness and technological capabilities in the BCI and robotics sectors [2] - The global BCI market is projected to grow to approximately $12.4 billion by 2034, with a compound annual growth rate (CAGR) of 17% from 2025 to 2034, driven by technological advancements and policy support [2]

Core Viewpoint - The brain-computer interface (BCI) concept stocks surged on the first trading day of 2026 in the A-share market, driven by significant developments in the industry, including Neuralink's plans for mass production of BCI devices and supportive policies for high-end medical devices [1][3]. Group 1: Stock Performance - Multiple BCI-related stocks, including Aipeng Medical, Xiangyu Medical, and Meihua Medical, reached their daily limit up, with Aipeng Medical rising by 20% to 33.30 CNY [2][1]. - Other notable performers included Sainuo Medical and Hanwei Technology, which saw increases of 17.31% and 15.99%, respectively [2][1]. - The overall trend in the Hong Kong market mirrored that of the A-share market, with stocks like Nanjing Panda Electronics rising over 30% [2][1]. Group 2: Industry Developments - Elon Musk's Neuralink announced plans to begin large-scale production of BCI devices in 2026, signaling a significant advancement in the field [3]. - The integration of artificial intelligence in healthcare is accelerating, with 207 AI medical devices expected to be approved by 2025, highlighting the rapid technological progress [3]. - The global BCI market is projected to reach $12.4 billion by 2034, with a compound annual growth rate (CAGR) of 17% from 2025 to 2034, indicating substantial growth potential [3]. - Recent policy support, including the inclusion of implantable BCI devices in a priority approval list by the National Medical Products Administration, is expected to further enhance the commercialization process [3].

据新华社旧金山电，埃隆·马斯克2025年12月31日通过社交平台发布重磅消息，旗下脑机接口公司 Neuralink计划于2026年启动脑机接口设备大规模量产，并同步推出全自动化外科手术流程。这一规划标 志着脑机接口技术从临床验证阶段向产业化落地迈出关键一步，也成为A股人脑工程板块的强力催化， 截至1月5日上午收盘，该板块指数大涨12.56%至6245.59点，超十只概念股收获"20CM"涨停。 据Neuralink官网及马斯克公开发言内容，截至2025年9月份，该公司已完成12例脑机接口设备人体植入 手术，临床试验参与者累计使用设备时长超1.5万小时，患者可通过意念实现光标操控、文字输入甚至 机械臂辅助进食等操作，设备实际运行稳定性达标率超98%。同时，第二代手术机器人实现技术升级， 将单根电极植入时间从17秒压缩至1.5秒，整体手术时长从6小时缩短至20分钟内；成本端也实现大幅下 降，单台设备植入成本从早期百万美元级降至10万美元以内，全自动化手术落地后有望进一步下探至5 万美元区间。 《证券日报》记者注意到，A股相关上市公司早已在脑机接口赛道展开布局，从设备研发到临床应用多 维度切入，试图抢占行业发展先机 ...

Market Overview - The A-share market saw a strong opening on January 5, with the Shanghai Composite Index returning to 4000 points, closing at 4011.45, up 1.07% [1] - The Shenzhen Component Index rose by 1.87%, and the ChiNext Index increased by 2.15% [1] Trading Volume - The total trading volume in the Shanghai and Shenzhen markets reached 1.64 trillion yuan, an increase of 323.8 billion yuan compared to the previous trading day [3] Stock Performance - A total of 4064 stocks rose, with 99 stocks hitting the daily limit, while 1236 stocks declined [3] - The sectors that performed well included insurance, medical devices, semiconductors, and gaming, with brain-computer interface concept stocks experiencing significant gains [3] Sector Highlights Brain-Computer Interface - Brain-computer interface stocks surged, with several companies hitting the daily limit [6] - Notable performers included Xiangyu Medical, Guanhao Biological, Meihua Medical, Aipeng Medical, and Lepu Medical, all recording a 20% increase [6][7] - Elon Musk's Neuralink announced plans for large-scale production of brain-computer interface devices by December 31, 2026, which is expected to revolutionize the field by reducing invasiveness [9] Semiconductor Sector - The semiconductor sector also showed strength, with multiple stocks reaching their daily limit [10] - Key performers included Dongwei Semiconductor and *ST Tianlong, both achieving a 20% increase [11] - TSMC announced it received U.S. government approval to import chip manufacturing equipment to its Nanjing facility in 2026, which is a positive development for the sector [12] Insurance Sector - The insurance sector experienced a rally, with significant gains from major companies [13] - Xinhua Insurance rose by 7.53%, China Pacific Insurance by 6.16%, and China Life Insurance by over 5% [13][14] - The insurance industry reported a total premium income of 57.629 billion yuan for the first 11 months of 2025, a year-on-year increase of 7.6% [14]

Market Performance - On January 5, 2026, the A-share market opened strongly, with the Shanghai Composite Index returning to 4000 points after 34 trading days, closing at 4011 points with an increase of over 1% [1] - The Shenzhen Component Index and the ChiNext Index rose by 1.87% and 2.15% respectively, with over 4000 stocks in the market experiencing gains [1] Brain-Computer Interface Sector - The brain-computer interface sector showed significant activity, rising over 13% by midday, with key stocks such as Beikang reaching a 30% limit up, and others like Sanbo Brain Science, Aipeng Medical, and Dineke hitting 20% limit up [1] - Elon Musk announced that his brain-computer interface company, Neuralink, plans to begin large-scale production of brain-computer interface devices in 2026, transitioning to a more streamlined and nearly fully automated surgical process [1] Aerospace and Precious Metals - In the commercial aerospace sector, stocks like Huazhu Gaoke and Feiwo Technology saw increases of 13.87% and 12.95% respectively, while Aerospace Hanyu rose over 10% [1] - In the precious metals sector, Hunan Silver and Hunan Gold increased by 9.68% and 2.7% respectively [1] - In the smart medical field, stocks such as Kefu Medical, Guhan Medicine, and Dahu Co. rose over 6% [1]

【导读】上午A股三大指数集体大涨，半导体、保险板块大涨，脑机接口概念股掀"涨停潮" 大家好，今天是2026年第一个交易日，基金君和你继续关注市场行情！ 1月5日上午，A股三大股指高开高走，沪指重返4000点，超4000只个股上涨，近百只个股涨停。截至午间收盘，沪指报4011.45点，涨1.07%，深证成指涨 1.87%，创业板指涨2.15%。 沪深两市半日成交额达1.64万亿元，较上个交易日放量3238亿元。个股涨多跌少，全市场共4064只个股上涨，99只个股涨停，有1236只个股下跌。 个股方面，翔宇医疗、冠昊生物（300238）、美好医疗（301363）、爱朋医疗（300753）、乐普医疗（300003）录得20cm涨停，三七互娱（002555）、 创新医疗（002173）、航天长峰（600855）录得10cm涨停。 | 代码 | 名称 | 现价 | 涨跌幅 ▼ | 总市值1 | 年初至今涨跌幅 | | --- | --- | --- | --- | --- | --- | | 688626 | 翔宇医疗 | 72.60 | 20.00% | 116亿 | 20.00% | | 300238 | 冠昊生物 ...

一、【早盘盘面回顾】 智通财经1月5日讯，市场早盘高开高走。时隔34个交易日，上证指数重回4000点，创业板指涨超2%。 沪深两市半日成交额1.64万亿，较上个交易日放量3238亿。盘面上热点快速轮动，全市场超4000只个股 上涨，其中98只个股涨停。从板块来看，脑机接口概念爆发，二十余只成分股涨停，三博脑科、美好医 疗、创新医疗、倍益康、塞力医疗涨停。商业航天概念反复活跃，中国卫通5天3板。保险板块走强，新 华保险、中国太保双双续创历史新高。半导体产业链表现活跃，亚翔集成、圣晖集成涨停。下跌方面， 海南自贸概念集体大跌，海南发展跌停。截至收盘，沪指涨1.07%，深成指涨1.87%，创业板指涨 2.15%。 个股来看，今日早盘涨停数量为79家（不包括ST及未开板新股），封板率为77%，连板股数量为14家， 锋龙股份7连板，雷科防务4连板，南兴股份3连板，农心科技、利欧股份、北斗星通、友邦吊顶、王子 新材、索菱股份、中天火箭、顺控发展、城建发展、烽火通信、中国卫通2连板。 板块上，脑机接口全线爆发，博拓生物、航天长峰、倍益康、三博脑科、翔宇医疗、伟思医疗、诚益 通、爱朋医疗、创新医疗等20余股涨停。 | | | ...

1月5日，时隔34个交易日，上证指数盘中重回4000点。 商业航天概念大面积高开 1月5日早盘商业航天概念大面积高开，金风科技、雷科防务、联创光电等多股涨停，久之洋、北斗星通、中国卫星、顺灏股份等高开超5%。 板块题材上，脑机接口、保险、半导体、商业航天、创新药、游戏、有色金属板块涨幅居前；海南自贸区、旅游及酒店、银行、跨境支付、猪肉板块跌幅 居前。 脑机接口板块掀涨停潮 脑机接口板块早盘掀起涨停潮，倍益康30cm涨停，三博脑科（301293）、美好医疗（301363）、翔宇医疗等超20股涨停。 消息面上，马斯克近日在社交媒体上表示，其脑机接口公司Neuralink将于2026年开始对脑机接口设备进行"大规模生产"，并同步推进一种流程高度精简、 几乎完全自动化的手术方案。 马斯克表示，接下来设备中的电极丝将直接穿过硬脑膜，而无需将其切除——这是一项非常重大的突破。 | 大盘 | 板块 | 个股 | 看盘广场 | | --- | --- | --- | --- | | 图午间休盘 | | | -21.47亿 大盘资金净流入 | | 13:00 继续开盘 | | | | | 上证指数 | 深证成指 | | 创业板 ...

Core Viewpoint - The A-share market experienced a significant surge on January 5, 2026, driven by the brain-computer interface (BCI) sector, with the index rising over 12% and multiple stocks hitting their daily limit up [1] Group 1: Market Performance - On the opening day of the A-share market, stocks related to brain-computer interfaces saw a collective rally, with stocks like BeiYikang (920199.BJ) hitting a 30% limit up and others such as Botao Bio (688767.SH) and Sanbo Neuroscience (301293.SZ) reaching 20% limit up [1] - A total of 11 stocks in the BCI sector experienced a 20% limit up, indicating strong investor interest and market momentum [1] Group 2: Technological Developments - The surge in the BCI sector was catalyzed by news of mass production of BCI devices by Elon Musk's company, Neuralink, expected to begin in 2026, which includes advancements in surgical procedures [1] - Neuralink's device will feature electrodes that can penetrate the dura mater without removal, marking a significant technological breakthrough [1] Group 3: Domestic Developments - In China, several companies are emerging that parallel Neuralink's technological approach, with Guotai Junan Securities declaring 2025 as the year for clinical trials of invasive and semi-invasive BCIs [2] - Companies like Borui Kang have completed clinical trials, with expectations for regulatory approval in 2026, while other firms are also making progress in BCI technology [2] Group 4: Market Projections - Open Source Securities predicts that BCI technology will redefine human-robot interaction and is expected to commercialize by 2026, expanding from medical applications to AI and robotics [3] - The global BCI market is projected to grow to approximately $12.4 billion by 2034, with a CAGR of 17% from 2025 to 2034, indicating strong future growth potential [3]